Latest News & Features
.jpg/r%5Bwidth%5D=1280&r%5Bheight%5D=720/7eba27a0-50e4-11f0-9c85-f9a65cb3cc5f-Coke%20Morgan%20Stewart(1).webp)
Americas
Coke Morgan Stewart has issued a raft of decisions under new guidance intended to improve the US patent appeals board process. But it’s a divisive issue, finds Sarah Speight. 24 June 2025
Americas
David Gindler of Orrick discusses the US Supreme Court’s ruling in Amgen v. Sanofi and what it means for ongoing Section 112 litigation. The session considers how the decision has been applied – and how it may continue to be applied – by the Federal Circuit, district courts, and the PTAB, with a focus on its relevance to the life sciences sector. 23 June 2025
Europe
Court sets strict rules on rehearing's, saying "only fundamental procedural defects can be the basis for a rehearing” | Follows UK blow to Alexion, allowing biosimilars onto market. 20 June 2025
Americas
Regeneron files motion to disqualify firm from patent and antitrust dispute | Motion cites conflict of interest due to Kirkland’s prior work for Regeneron | Kirkland denies conflict, citing screening measures. 19 June 2025
Americas
The biotech firm strikes again over Eylea after Amgen launches biosimilar | Regeneron claims Amgen infringed agreed ‘patent dance’ | Follows other lawsuits aimed at protecting Eylea. 19 June 2025
Europe
Despite efforts to harmonise, the Unified Patent Court’s local divisions and Court of Appeal have signalled a divergence over implementing the European Patent Convention—but does it matter? Chris Moore and Hsu Min Chung of HGF report. 19 June 2025
Careers
Former in-house counsel at major pharma companies brings expertise in IP strategy, regulatory compliance, and business development across pharma and biotech. 19 June 2025
Europe
Court affirms infringement of patent covering gene expression technology | Curio Bioscience cannot sell related products in three EU countries | Decision is “further testament to 10x Genomic’s strategic use of IP”, 10x counsel tells LSIPR. 17 June 2025
Americas
Semaglutide generics set to enter the Canadian market by 2026 after Novo Nordisk failed to maintain key patent | Speculation over whether it was a mistake or calculated move in a country known for strict drug price controls. 17 June 2025
Careers
Ex-co-head of life sciences at previous firm brings expertise in multi-jurisdictional patent disputes involving supplementary protection certificates and second medical use claims. 17 June 2025